Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 9/20 | 0.70 |
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | TPO | P07202 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22249597 | 0.85 | NLRP3 (0.68) | NLRP3TLR7KCNH2HTR2A | |
| SCHEMBL22249449 | 0.83 | NLRP3 (1.00) | NLRP3 | |
| SCHEMBL22249415 | 0.81 | NLRP3 (0.73) | NLRP3 | |
| SCHEMBL22249413 | 0.77 | NLRP3 (0.67) | NLRP3 | |
| SCHEMBL22249450 | 0.77 | NLRP3 (0.67) | NLRP3 | |
| SCHEMBL22249414 | 0.77 | NLRP3 (0.67) | NLRP3 | |
| SCHEMBL22249451 | 0.77 | NLRP3 (0.72) | NLRP3 | |
| SCHEMBL22249598 | 0.76 | NLRP3 (0.66) | NLRP3 | |
| SCHEMBL22249257 | 0.76 | NLRP3 (0.66) | NLRP3 | |
| SCHEMBL22249392 | 0.76 | NLRP3 (0.68) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089571-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| WO-2020150113-A1 | SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089571-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | NLRP3 1/4885TLR7 245/4885KCNH2 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.